Physician profile
Jackilyn Byrd
NPI 1982273975
$1,017.93
in general payments reported to CMS, 2019-2025
18 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.39 · 2022: $257 · 2023: $224 · 2024: $127 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $343.35 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Indivior INC. | $91.73 | 2024-2025 | Sublocade |
| Pfizer INC. | $77.17 | 2022-2024 | |
| Abbvie INC. | $72.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $68.66 | 2022-2025 | Airsupra |
| Uswm, LLC | $63.58 | 2022-2023 | Zimhi, Lucemyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.36 | 2025 | Caplyta |
| Novo Nordisk INC | $35.49 | 2022-2025 | |
| Exact Sciences Corporation | $29.49 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $29.16 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $28.08 | 2021 | |
| Dexcom, INC. | $26.85 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.00 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.32 | 2025 | Invega Trinza, Invega Sustenna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.93 | 2023 | |
| Braeburn INC. | $13.55 | 2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackilyn Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.